- The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysAs drugmakers prepare for the looming biopharma patent cliff, 2026 has so far been a year for dealmaking. Now, contract manufacturers need to broaden their services to keep up, Fujifilm Biotechnolo…Endpoints · 23h ago↗ source
- ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugA new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.Fierce Biotech · 23h ago↗ source
- Capricor's DMD therapy lacks efficacy, FDA says ahead of adcommThe FDA is again questioning the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday. The agency's review team said…